Purple Biotech Stock Fundamentals
| PPBT Stock | USD 8.40 5.04 150.00% |
Purple Biotech fundamentals help investors to digest information that contributes to Purple Biotech's financial success or failures. It also enables traders to predict the movement of Purple Stock. The fundamental analysis module provides a way to measure Purple Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Purple Biotech stock.
At this time, Purple Biotech's Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 2.3 M in 2024, despite the fact that EBIT is likely to grow to (21.3 M). Purple | Select Account or Indicator |
Purple Biotech Company Return On Equity Analysis
Purple Biotech's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Purple Biotech Return On Equity | -0.45 |
Most of Purple Biotech's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Purple Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Purple Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Purple Biotech has a Return On Equity of -0.4467. This is 98.14% lower than that of the Biotechnology sector and 98.77% lower than that of the Health Care industry. The return on equity for all United States stocks is 44.1% higher than that of the company.
Purple Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Purple Biotech's current stock value. Our valuation model uses many indicators to compare Purple Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Purple Biotech competition to find correlations between indicators driving Purple Biotech's intrinsic value. More Info.Purple Biotech is regarded third in return on equity category among its peers. It also is regarded third in return on asset category among its peers . At this time, Purple Biotech's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Purple Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Purple Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Purple Biotech's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Purple Biotech could also be used in its relative valuation, which is a method of valuing Purple Biotech by comparing valuation metrics of similar companies.Purple Biotech is currently under evaluation in return on equity category among its peers.
Purple Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Purple Biotech from analyzing Purple Biotech's financial statements. These drivers represent accounts that assess Purple Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Purple Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 14.3M | 44.8M | 67.6M | 26.2M | 20.2M | 16.9M | |
| Enterprise Value | 10.1M | 34.5M | 57.4M | 11.7M | 6.1M | 11.0M |
Purple Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Purple Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Purple Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Purple Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 5.04 M | ||||
| Shares Outstanding | 1.57 M | ||||
| Shares Owned By Insiders | 2.86 % | ||||
| Shares Owned By Institutions | 9.33 % | ||||
| Number Of Shares Shorted | 34.62 K | ||||
| Price To Book | 0.45 X | ||||
| Price To Sales | 58.08 X | ||||
| Gross Profit | (120 K) | ||||
| EBITDA | (22.23 M) | ||||
| Net Income | (19.88 M) | ||||
| Cash And Equivalents | 36.02 M | ||||
| Cash Per Share | 2.00 X | ||||
| Total Debt | 351 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.94 X | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (19.23 M) | ||||
| Short Ratio | 0.43 X | ||||
| Earnings Per Share | 81.00 X | ||||
| Target Price | 33.0 | ||||
| Number Of Employees | 20 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 13.16 M | ||||
| Total Asset | 44.3 M | ||||
| Retained Earnings | (137.45 M) | ||||
| Working Capital | 8.61 M | ||||
| Net Asset | 44.3 M |
About Purple Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Purple Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Purple Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Purple Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.1 M | 580.8 K | |
| Cost Of Revenue | 196 K | 189.9 K | |
| Stock Based Compensation To Revenue | 11.01 | 8.22 | |
| Sales General And Administrative To Revenue | 6.98 | 6.63 | |
| Research And Ddevelopement To Revenue | 78.30 | 82.21 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Ebit Per Revenue | 102.37 | 107.49 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.